ArticleBMC microbiology2025
Immunogenicity of a bivalent recombinant adenovirus expressing VP1 proteins of bovine norovirus and bovine nebovirus in mice and calves.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Epidemiological Features of Calicivirus Infections in Cattle.Animals : an open access journal from MDPI · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine norovirus (BNoV) and bovine nebovirus (BNeV) are emerging pathogens responsible for severe diarrhea in calves worldwide. In this study, we constructed a bivalent recombinant adenovirus vector vaccine, designated rAd5-BNoV + BNeV_VP1 encoding the genes for BNoV-VP1 and BNeV-VP1 based on replication-deficient human adenovirus type 5 (rAd5), and evaluated its immunogenicity in mice and calves. Serum antibody responses were assessed by enzyme-linked immunosorbent assay (ELISA) and serum blocking titer 50 (BT50). Results demonstrated that mice immunized with rAd5-BNoV + BNeV_VP1 produced significant VP1-specific IgG titers as early as two weeks post-vaccination. BNoV-VP1-specific IgG antibody titers peaked at 1:10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.